Wells Fargo reiterated an Equal Weight rating and $2 price target on Adaptimmune (ADAP), saying he believes the Galapagos (GLPG) collaboration is a “rational move” to bring in additional capital to support the sarcoma launch and ovarian pivottal study. The firm added, however, that the move would present a compromise of reduced economic exposure to the head & neck cancer and urothelial cancer opportunities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Inks Lucrative Deal for Cancer Therapy Trial
- Scotiabank starts Adaptimmune at Outperform ahead of ‘imminent’ launches
- Adaptimmune initiated with an Outperform at Scotiabank
- Adaptimmune price target lowered to $3 from $9 at Mizuho
- Adaptimmune Secures $125M Loan for Corporate Growth and Product Development
Questions or Comments about the article? Write to editor@tipranks.com